Innovation Driving Opportunities For Active Transdermal Drug Delivery Analysis By Greystone Associates Reveals Market And Technology Factors
Jan 29th 2008Drug InformationDermatology
With compliance concerns continuing to drive investment in new drug delivery technologies, interest in transdermal delivery systems is proliferating. But as work with passive transdermal systems has progressed, so too has the realization of the true extent of the barrier to drug delivery presented by the stratum corneum, the skin’s outer layer of dead cells.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
